Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives

Immune checkpoint inhibitors (ICIs), especially anti-programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies, have made dramatic progress in the treatment of lung cancer, especially for patients with cancers not driven by oncogenes. However, responses are limited to a subset of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Chang, Zhang, Yi-Chen, Chen, Zhi-Hong, Zhou, Qing, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963952/
https://www.ncbi.nlm.nih.gov/pubmed/35359372
http://dx.doi.org/10.3389/fonc.2022.836891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963952/
https://www.ncbi.nlm.nih.gov/pubmed/35359372
http://dx.doi.org/10.3389/fonc.2022.836891

Ejemplares similares